xT CDx is a sophisticated next-generation sequencing platform designed to profile solid tumors through both DNA and RNA analysis. A key feature of this device is its capacity to pinpoint single nucleotide variants, multiple nucleotide variants, and insertion-deletion alterations across 648 genes, thereby offering comprehensive genomic insights. Furthermore, this tool examines microsatellite instability (MSI) using DNA samples taken from formalin-fixed, paraffin-embedded tumor tissues, alongside matched normal blood or saliva specimens. The platform also functions as a companion diagnostic (CDx) for identifying patients who may benefit from various targeted cancer therapies. Integrated with Tempus's robust sequencing capabilities, xT CDx provides healthcare professionals with critical mutation profiles that adhere to oncology professional guidelines, facilitating more precise treatment pathways. By leveraging comprehensive genomic data, xT CDx plays a vital role in enhancing personalized cancer care.
